GENMAB - Dusseldorf Stock Exchang (GE9 DU) stock market data APIs
€272.8403
0.11(0%)
as of December 30, 2025
Try our APIs with
free plan!
GENMAB - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GE9.DU.
Prev. Close
272.8403
Open
272.9462
High
274.1444
Low
271.2481
52 wk Range
157-286.8
Market Cap
22 148 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GENMAB - Dusseldorf Stock Exchang data using free add-ons & libraries
Get GENMAB - Dusseldorf Stock Exchang Fundamental Data
GENMAB - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GENMAB - Dusseldorf Stock Exchang News
New
Here’s Why Genmab A/S (GMAB) Rose in Q3
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua International and Gl...
Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says
Genmab (GMAB) can expect a "transformative" year ahead, with five to six pivotal trial readouts for PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Genmab to discontinue further development of acasunlimab
Genmab (GMAB) announced that it will discontinue further clinical development of acasunlimab. This decision does not impact Genmab’s full-year 2025 financial guidance. “After careful consideration...
Genmab Portfolio Prioritization Update
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
